Viola D'Ambrosio

MD, PhD - Consultant Nephrologist at FPG 🩺 Interested in Rare Kidney Diseases 🫘Renal physiology enthusiast 🔬 All things tubule 🛰️

[Viola D'Ambrosio @Violadmb]

🚨 Out now!

Curious to know what happens to your kidneys when you go to space? 🚀
#CosmicKidneyDisease @NatureComms

So proud to be part of this amazing work led by @KeithSiew and #StephenBWalsh at @LTubularCentre @RenalUCL 🪐

https://t.co/ih1gWm5KlS

[ERA - European Renal Association @ERAkidney]

📢 Join us at the new e-seminar from the series "CKD and genetic disease: a broader approach": *Kidney stones – moving towards targeted treatment*

📅 May 7, 2026 at 5:00 PM (CEST)

Register now 👉 https://t.co/4fzvaTU52i

[Mayo Clinic Nephrology @MayoClinicNeph]

Bayesian Methods in Nephrology: Applications in Adaptive Trials, Dynamic Risk Prediction, Pharmacokinetics, and Causal Inference

@wisit661 @FrancescoPesce @NDTsocial @ERAkidney

https://t.co/B2E8Utnbmo

[Mónica Furlano MD, PhD @m_furlano]

🧬SAVE THE DATE November 23-24, 2026

@FPuigvert and @torra_roser are presenting an innovative course on #genetics and #kidneydiseases, bringing together leading international experts. You can view the program in the image.

👇🏻Registration👇🏻
https://t.co/mmf74RzTeo

[Roser Torra @torra_roser]

Being at #SIN2025 feels like being at home, meeting so many friends and colleagues I truly admire. The SIN is doing an outstanding job raising awareness on #CKD and empowering young nephrologists. Congratulations on an extremely successful congress! 👏@SinReni

[YNP of ERA @ynptweets]

1/ 🧬 CRISPR and gene editing for kidney diseases: Where do we stand in 2025?
A review on how CRISPR and other gene editing tools are redefining what’s possible in nephrology — from fixing mutations to regenerating kidney tissue.

@Violadmb is the YNP author
🧵 by @jt_nephrology
@CKJsocial @ERAkidney

[Francesco Pesce @FrancescoPesce]

Our study on cardiac complications in Autosomal Dominant Polycystic Kidney Disease (ADPKD) on @ERAkidney @CKJsocial reveals key insights:
🔍 PKD1 mutations independently increase the risk of left ventricular hypertrophy, beyond hypertension and other factors;
❤️ Aortic regurgitation is linked to greater disease severity;
🧬 Mitral valve prolapse is associated with truncating PKD1 mutations highlighting genotype-specific risks.
These findings have important implications for personalized cardiovascular monitoring and management in ADPKD patients. Genotype matters! 💡

Read the full open-access article here: https://t.co/y46JxwY2h2

[Camillo Tancredi Strizzi @CTStrizzi]

Where does aldosterone actually do its work? In the aldosterone-sensitive distal nephron (ASDN): DCT2, CNT, and the collecting duct.
The control room for Na⁺ balance and K⁺ homeostasis. (Follow the thread 🧵)
#Nephpearls #Nephrology #Physiology

[Camillo Tancredi Strizzi @CTStrizzi]

🧵1. Aldosterone isn’t just “salt & water.” In modern sodium-rich contexts it drives inflammation, fibrosis, and residual cardiorenal risk. We map physiology → disease → therapies, and argue for reprogramming the signal. Follow the thread ---> https://t.co/VLpwPTVvh8

[Diego Toso @KidneyToso]

Cystinosis usually needs early and strict cysteamine treatment.
Yet this case had a good outcome despite late and unconventional therapy 👉 https://t.co/GY9ctqVmgK
#Nefrologìa #nephrology #Cystinosis
@torra_roser @m_furlano

[YNP of ERA @ynptweets]

Meet & Greet was a success! Thanks to all participants! 🎉

#ERA25 @ERAkidney

[Roser Torra @torra_roser]

Thank you for helping boost nephrology beyond imagination at the most incredible @ERAkidney Congress ever! With over 10.000 attendees and phenomenal sessions. 🇦🇹

[UCL Renal Genomics @RenalGenomics]

Congratulations to @OAlavijeh for a wonderful presentation and his Raine award #UKKW25!

[Diego Toso @KidneyToso]

Grateful and proud to give my first talk at #ERA25

[Roser Torra @torra_roser]

Special thanks for the huge support and extremely nice messages I have received from so many 👩🏻‍⚕️👩🏻‍⚕️👩🏻‍⚕️👩🏻‍⚕️ in #ERA2025

[London Tubular Centre @LTubularCentre]

Check our latest paper on the mouse strain-specific spaceflight-induced changes in kidney gene expression after flying🚀 to the ISS🛰️.

https://t.co/FhN65IUpFx

[London Tubular Centre @LTubularCentre]

Check out @KeithSiew on @theldnstandard
#TheStandard #TechScienceDaily Podcast talking about the health consequences of #spaceflight and what an #AstronautsReturn can expect to do recover their health.

https://t.co/rXvTWqWiWt

[United Nations @UN]

Simple steps can help protect your kidneys:

⚖️ Maintain a healthy body weight
🥗 Eat a nutritious diet
🏃🏽‍♀️ Be active
💧 Drink water
🚭 Don't smoke
❤️ Control your blood pressure
💊 Don't self-medicate

Thursday is #WorldKidneyDay: https://t.co/fWVDbH0nCk

via @pahowho

[Flavia Galletti @FLAVIAZH]

🌍Today is @worldkidneyday ! Have you checked your kidneys?

Understanding risk factors & monitoring your #KidneyHealth can help protect your life.

At your next doctor’s visit, ask to check your kidney values! Early detection saves lives!
#WorldKidneyDay2025 #AreYourKidneysOK

[London Tubular Centre @LTubularCentre]

🚨Booking Open🚨
UCL’s Applied Renal Physiology Course (14-16 May 2025) is now open for registration!
🔑 3 days of learning on electrolyte imbalances, hypertension, and fluid management.
🎓 2 Bursaries Available!
💸 Early Bird – Book by 28th Feb!
🔗 Book: https://t.co/RuJH1SJnDV

[KDIGO @goKDIGO]

We are pleased to announce the publication of the KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Read the news release: https://t.co/fYJJ7yupq5

This first-ever KDIGO guideline focused on a rare kidney disease provides practical tools for healthcare providers and patients to improve diagnosis, care, and treatment, addressing challenges in managing this inherited condition.

"This comprehensive guideline reflects the significant progress in ADPKD research over the last decade, from genetic insights to advanced therapies," said Guideline Co-Chair Vicente E. Torres, MD. "By addressing the complexities of diagnosis, treatment, and management, we hope this guideline will standardize care, enhance clinical practices, and help reduce the global burden of ADPKD. Our goal is that this resource will not only empower clinical decision-making but also inspire hope for patients and their families, demonstrating that meaningful progress is achievable for this challenging disease."

"The publication of this guideline represents a pivotal step forward in the care of ADPKD and people with rare genetic disorders worldwide," said Guideline Co-Chair Olivier Devuyst, MD. "It is the result of an extraordinary global collaboration among experts, researchers, and patient advocates, bringing together the best available evidence to guide care across diverse settings. This guideline is not just important for individuals with ADPKD. It also serves as a crucial template for the development of guidance for other rare genetic conditions. By providing a roadmap for consistent, evidence-based care, it addresses critical knowledge and practice gaps worldwide, offering a model for improving the lives of those with rare diseases globally."

Download the KDIGO ADPKD Guideline, Executive Summary, and Data Supplement on the guideline website: https://t.co/8owEw5VMSa

Read the guideline in @Kidney_Int: https://t.co/feuj6Pbj0D

#ADPKD